Nadia Harbeck Selected Research

Trastuzumab (Herceptin)

1/2023	Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
1/2023	De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
10/2022	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
3/2022	Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
1/2022	De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
11/2021	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.
10/2021	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
1/2021	Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
9/2020	Trastuzumab Biosimilars in the Therapy of Breast Cancer - "Real World" Experiences from four Bavarian University Breast Centres.
1/2019	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nadia Harbeck Research Topics

Disease

343	Breast Neoplasms (Breast Cancer) 05/2024 - 01/2002
179	Neoplasms (Cancer) 03/2024 - 01/2002
29	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2002
19	Triple Negative Breast Neoplasms 01/2024 - 11/2015
17	Neutropenia 02/2024 - 06/2009
16	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 06/2003
15	Pathologic Complete Response 01/2023 - 06/2009
14	Disease Progression 01/2022 - 06/2004
11	Fatigue 01/2024 - 05/2014
10	COVID-19 01/2023 - 01/2020
9	Carcinoma (Carcinomatosis) 04/2021 - 02/2002
9	Febrile Neutropenia 02/2021 - 04/2006
7	Leukopenia 01/2023 - 01/2010
6	Nausea 12/2023 - 07/2009
6	Anemia 12/2020 - 03/2009
5	Brain Neoplasms (Brain Tumor) 06/2022 - 01/2007
5	Pain (Aches) 01/2020 - 01/2018
4	Diarrhea 02/2024 - 04/2019
4	Vomiting 12/2023 - 06/2016
4	Alopecia (Baldness) 12/2023 - 07/2009
4	Residual Neoplasm 09/2022 - 03/2007
4	Cardiotoxicity 09/2021 - 05/2005
4	Infections 02/2021 - 06/2009
4	Circulating Neoplastic Cells 01/2019 - 12/2015

Drug/Important Bio-Agent (IBA)

96	Hormones (Hormone)IBA 04/2024 - 01/2002
48	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2002
37	Trastuzumab (Herceptin)FDA Link 01/2023 - 01/2003
32	ErbB Receptors (EGF Receptor)IBA 02/2024 - 03/2010
30	human ERBB2 proteinIBA 01/2023 - 12/2009
24	AnthracyclinesIBA 10/2022 - 04/2006
22	Proteins (Proteins, Gene)FDA Link 04/2024 - 01/2002
20	palbociclibIBA 01/2024 - 07/2015
20	Plasminogen Activator Inhibitor 1IBA 07/2019 - 01/2002
20	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2016 - 01/2002
18	Estrogen ReceptorsIBA 01/2024 - 07/2004
18	Docetaxel (Taxotere)FDA Link 03/2023 - 01/2006
17	Epirubicin (Ellence)FDA LinkGeneric 10/2022 - 03/2007
15	Fulvestrant (Faslodex)FDA Link 10/2023 - 01/2011
15	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 11/2009
13	Tamoxifen FDA LinkGeneric 01/2023 - 07/2004
13	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 03/2007
12	Letrozole (Femara)FDA LinkGeneric 01/2024 - 01/2007
12	Ado-Trastuzumab EmtansineIBA 01/2023 - 01/2014
11	abemaciclibIBA 04/2024 - 04/2019
11	Aromatase InhibitorsIBA 05/2023 - 12/2007
11	SteroidsIBA 01/2020 - 01/2002
11	Tissue ExtractsIBA 11/2010 - 01/2002
10	taxaneIBA 10/2022 - 01/2008
10	Messenger RNA (mRNA)IBA 01/2022 - 07/2003
10	Progesterone Receptors (Progesterone Receptor)IBA 01/2022 - 02/2005
9	Cyclin-Dependent Kinase 4IBA 09/2023 - 01/2017
9	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 12/2011
8	ParaffinIBA 02/2024 - 11/2008
8	Phenobarbital (Luminal)FDA Link 01/2023 - 12/2013
8	pertuzumabIBA 01/2023 - 03/2013
8	Lapatinib (GW572016)FDA Link 10/2021 - 01/2008
8	Plasminogen InactivatorsIBA 07/2011 - 01/2002
7	Formaldehyde (Formol)FDA Link 02/2024 - 11/2008
7	ribociclibIBA 09/2023 - 01/2018
7	130-nm albumin-bound paclitaxelIBA 09/2022 - 12/2015
7	AntigensIBA 01/2022 - 08/2002
7	Capecitabine (Xeloda)FDA Link 10/2021 - 08/2005
7	Gemcitabine FDA Link 04/2021 - 11/2015
7	Fluorouracil (Carac)FDA LinkGeneric 12/2020 - 08/2005
7	EnzymesIBA 09/2017 - 02/2002
7	Indicators and Reagents (Reagents)IBA 11/2009 - 06/2003
6	pembrolizumabIBA 12/2023 - 01/2020
6	Immunoconjugates (Immunoconjugate)IBA 10/2023 - 10/2013
6	Taxoids (Taxanes)IBA 10/2022 - 04/2006
6	RNA (Ribonucleic Acid)IBA 11/2021 - 04/2006
6	Biological FactorsIBA 10/2021 - 01/2002
6	Biosimilar PharmaceuticalsIBA 09/2020 - 01/2016
6	Tumor Biomarkers (Tumor Markers)IBA 07/2011 - 11/2004
6	Kallikreins (Kallikrein)IBA 03/2006 - 06/2003
5	atezolizumabIBA 03/2023 - 01/2020
5	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 05/2005
5	pegfilgrastim (Neulasta)FDA Link 02/2021 - 01/2016
5	DNA (Deoxyribonucleic Acid)IBA 12/2017 - 04/2006
5	Serine Proteases (Serine Protease)IBA 10/2010 - 01/2006
5	ImmunosorbentsIBA 01/2006 - 02/2002
4	Epidermal Growth Factor (EGF)IBA 04/2024 - 12/2008
4	Cadherins (E-Cadherin)IBA 04/2024 - 10/2018
4	trastuzumab deruxtecanIBA 10/2023 - 01/2022
4	sacituzumab govitecanIBA 03/2023 - 04/2021
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2022 - 01/2019
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2020 - 04/2006
4	LigandsIBA 10/2020 - 02/2005
4	Anastrozole (Arimidex)FDA LinkGeneric 06/2020 - 12/2007
4	Transcription Factors (Transcription Factor)IBA 01/2018 - 07/2007

Therapy/Procedure

205	Therapeutics 05/2024 - 02/2002
102	Drug Therapy (Chemotherapy) 05/2024 - 01/2002
40	Neoadjuvant Therapy 01/2024 - 01/2009
32	Adjuvant Chemotherapy 02/2024 - 08/2002
18	Radiotherapy 02/2024 - 01/2007
10	Segmental Mastectomy (Lumpectomy) 04/2023 - 05/2006
7	Aftercare (After-Treatment) 05/2024 - 03/2008
6	Mastectomy (Mammectomy) 12/2021 - 03/2008
5	Drug Tapering 04/2024 - 01/2006
5	Precision Medicine 06/2020 - 09/2008
4	Immunotherapy 10/2022 - 01/2010